RAB0328

Human VEGF R2 ELISA Kit

Name: Human VEGF R2 ELISA Kit
Brand: SIGMA

for serum, plasma, cell culture supernatant and urine

Select a Size

All Photos(2)

About This Item

NACRES:

NA.84

UNSPSC Code:

41116158

Product Name

Human VEGF R2 ELISA Kit, for serum, plasma, cell culture supernatant and urine

species reactivity

human

packaging

kit of 96 wells (12 strips x 8 wells)

technique(s)

ELISA: suitable
capture ELISA: suitable

input

sample type plasma
sample type serum
sample type cell culture supernatant(s)
sample type urine

assay range

inter-assay cv: <12%
intra-assay cv: <10%
sensitivity: 70 pg/mL
standard curve range: 34.3-25000 pg/mL

detection method

colorimetric

shipped in

wet ice

storage temp.

−20°C

Gene Information

human ... KDR(3791)

Related Categories

Enzyme-Linked Immunosorbent Assay (ELISA) Kits

Immunoassay Platform Solutions

Application

For research use only. Not for use in diagnostic procedures.
Please refer to the attached General ELISA KIT Procedure (sandwich, competitive & Indirect ELISA)

General description

The Human VEGF R2 ELISA (Enzyme-Linked Immunosorbent Assay) kit is an in vitro enzyme-linked immunosorbent assay for the quantitative measurement of human VEGF R2 in serum, plasma, cell culture supernatants and urine.

Immunogen

Recombinant Human VEGFR2

Other Notes

A sample Certificate of Analysis is available for this product.
Please type the word sample in the text box provided for lot number.

pictograms

GHS05

signalword

Warning

hcodes

H290

pcodes

P234 - P390

Hazard Classifications

Met. Corr. 1

Storage Class

8A - Combustible corrosive hazardous materials

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Epithelial VEGF signaling is required in the mouse liver for proper sinusoid endothelial cell identity and hepatocyte zonation in vivo.

Teagan J Walter et al.

American journal of physiology. Gastrointestinal and liver physiology, 306(10), G849-G862 (2014-03-22)

Vascular endothelial growth factor (VEGF) is crucial for vascular development in several organs. However, the specific contribution of epithelial-VEGF signaling in the liver has not been tested. We used a mouse model to specifically delete Vegf from the liver epithelial

Heparin modification of a biomimetic bone matrix for controlled release of VEGF.

Sven Knaack et al.

Journal of biomedical materials research. Part A, 102(10), 3500-3511 (2013-11-02)

Bone regeneration using tissue engineered constructs requires strategies to effectively stimulate vascularization within such a construct that is crucial for its supply and integration with the host tissue. In this work, porous scaffolds of a collagen/hydroxyapatite nanocomposite were modified with

Expression of vascular endothelial growth factor in human ocular adnexal lymphoma.

Satoshi Kinoshita et al.

Investigative ophthalmology & visual science, 55(6), 3461-3467 (2014-05-16)

To examine the expression of VEGF in extranodal marginal zone B-cell lymphoma (EMZL) and reactive lymphoid hyperplasia (RLH) of human ocular adnexa, and analyze the correlation with the intratumoral microvessel density (MVD). Twenty-two EMZL and 16 RLH tissues were examined

Dual inhibition of cyclooxygenase-2 and soluble epoxide hydrolase synergistically suppresses primary tumor growth and metastasis.

Guodong Zhang et al.

Proceedings of the National Academy of Sciences of the United States of America, 111(30), 11127-11132 (2014-07-16)

Prostaglandins derived from the cyclooxygenase (COX) pathway and epoxyeicosatrienoic acids (EETs) from the cytochrome P450/soluble epoxide hydrolase (sEH) pathway are important eicosanoids that regulate angiogenesis and tumorigenesis. COX-2 inhibitors, which block the formation of prostaglandins, suppress tumor growth, whereas sEH

Low intravitreal angiopoietin-2 and VEGF levels in vitrectomized diabetic patients with simvastatin treatment.

Raimo Tuuminen et al.

Acta ophthalmologica, 92(7), 675-681 (2014-02-11)

To investigate the intravitreal levels of potent vasoactive, angiogenic and extracellular matrix remodelling factors in the diabetic patients with simvastatin treatment. This is an institutional, prospective, observational case-control study. Type-1 and type-2 diabetic patients on lipophilic simvastatin (N = 14)

View All Related Papers